Concepedia

Nathalie Fiaschi

NF

Statistics

Publications

11

Citations

1K

H-Index

10

Active since

1998

Affiliations

Regeneron (United States)(Current)

Stanford University

Rutgers Cancer Institute

Rutgers, The State University of New Jersey

Universitätsklinikum Würzburg

Nathalie Fiaschi is an author at Regeneron (United States) specializing in medicine, radiation oncology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

1998–2024

11

Publications

11

Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma

Assaf Magen, Pauline Hamon, Nathalie Fiaschi et al. · Nature Medicine · 2023 · 348 citations · Full text

, , +11

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

Alexander Stratigos, Aleksandar Sekulić, Ketty Peris et al. · The Lancet Oncology · 2021 · 266 citations · Full text

, , +5

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

Thomas U. Marron, Maria Isabel Fiel, Pauline Hamon et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 207 citations · Full text

, , +10

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Rajat Bannerji, John N. Allan, Jon Arnason et al. · Blood · 2019 · 55 citations

CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models

Joyce Wei, Welby Montalvo-Ortiz, Lola Yu et al. · Science Translational Medicine · 2022 · 49 citations

1–5 of 11